Interleukin-17

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Izokibep achieved the primary endpoint of ACR50 response in a phase 2b/3 psoriatic arthritis trial, and demonstrated sustained, “deepening” benefit in hidradenitis suppurativa, according to top-line data from its manufacturer.

SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.

In this video, Sebastian E. Sattui, MD, MS, discusses exciting research on polymyalgia rheumatica.

Among adults presenting with chest pain, those with CAD confirmed by angiography had significantly lower levels of the cytokines interleukin-4 and interleukin-17 compared with those without CAD, data show.

Among patients with polymyalgia rheumatica who relapse during glucocorticoid tapering, sarilumab is effective at enabling them achieve sustained remission and lowering cumulative glucocorticoid use, according to data.